Ascendis Pharma (ASND)
NASDAQ:ASND
ASND Stock Chart & Stats
$216.95
-$0.55(-0.40%)
At close: 4:00 PM EST
$216.95
-$0.55(-0.40%)
Day’s Range― - ―
52-Week Range$124.06 - $248.60
Previous CloseN/A
Volume129.18K
Average Volume (3M)647.20K
Market Cap
$13.32B
Enterprise Value$11.82B
Total Cash (Recent Filing)$615.78M
Total Debt (Recent Filing)$871.41M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 27, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding61,977,410
10 Day Avg. Volume441,509
30 Day Avg. Volume647,199
Financial Highlights & Ratios
PEG Ratio1.13
Price to Book (P/B)-67.58
Price to Sales (P/S)15.90
P/FCF Ratio252.17
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue16.47
Enterprise Value/Gross Profit19.09
Enterprise Value/Ebitda-146.54
Forecast
1Y Price Target
$293.77Price Target Upside35.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)4.3
Revenue Forecast (FY)$1.39B
Bulls Say, Bears Say
Bulls Say
Combination Therapy Clinical BenefitClinical data showing superior growth and proportionality when combining Yuviwel with Skytrofa support potential adoption of the combo as an enhanced treatment option for skeletal growth disorders.
Platform Validation And Commercial ReadinessConsistent long‑term results across multiple TransCon programs, together with an established commercial infrastructure, indicate readiness to launch and scale new products.
Regulatory Approval And Dosing ConvenienceRegulatory approval of Yuviwel for achondroplasia provides a weekly, no‑food‑required dosing option that could attract patients and prescribers seeking a more convenient alternative to daily therapy.
Bears Say
Competition From Oral AlternativesAn oral therapy offering greater dosing convenience could draw patients who want to avoid injections, potentially limiting market share for injectable treatments.
Gross‑to‑net DiscountsExpected gross‑to‑net discounts are likely to reduce near‑term net revenue for Yorvipath, weighing on short‑term top‑line performance despite uptake.
Payer Access And Reimbursement RiskPayer coverage hurdles and prior authorization requirements could constrain early uptake and require reliance on formulary exceptions to reach patients.
Ascendis Pharma News
ASND FAQ
What was Ascendis Pharma’s price range in the past 12 months?
Ascendis Pharma lowest stock price was $124.06 and its highest was $248.60 in the past 12 months.
What is Ascendis Pharma’s market cap?
Ascendis Pharma’s market cap is $13.32B.
When is Ascendis Pharma’s upcoming earnings report date?
Ascendis Pharma’s upcoming earnings report date is May 27, 2026 which is in 60 days.
How were Ascendis Pharma’s earnings last quarter?
Ascendis Pharma released its earnings results on Feb 11, 2026. The company reported -$0.635 earnings per share for the quarter, missing the consensus estimate of -$0.092 by -$0.543.
Is Ascendis Pharma overvalued?
According to Wall Street analysts Ascendis Pharma’s price is currently Undervalued.
Does Ascendis Pharma pay dividends?
Ascendis Pharma does not currently pay dividends.
What is Ascendis Pharma’s EPS estimate?
Ascendis Pharma’s EPS estimate is 0.34.
How many shares outstanding does Ascendis Pharma have?
Ascendis Pharma has 61,977,410 shares outstanding.
What happened to Ascendis Pharma’s price movement after its last earnings report?
Ascendis Pharma reported an EPS of -$0.635 in its last earnings report, missing expectations of -$0.092. Following the earnings report the stock price went down -1.531%.
Which hedge fund is a major shareholder of Ascendis Pharma?
Currently, no hedge funds are holding shares in ASND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascendis Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$293.77 (35.41% Upside)
$293.77 (35.41% Upside)
Blogger Sentiment
Bullish
ASND Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
127.54%
Trailing 12-Months
Asset Growth
25.25%
Trailing 12-Months
Company Description
Ascendis Pharma
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
ASND Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive and growth-focused: management reported strong commercial execution (notably Yorvipath and Skytrofa), meaningful pipeline and regulatory progress (including imminent PDUFA for TransCon CNP and compelling combination data), and a strengthened cash position with an ambitious operating cash flow outlook for 2026. Key headwinds include high operating expenses (which slightly exceeded 2025 revenue), a substantial noncash finance remeasurement loss, currency-driven revenue headwinds, and remaining access / penetration and competitive uncertainties. Taken together the positives around revenue momentum, pipeline advancement, partnerships, and a stronger financial base outweigh the near-term financial and market-access challenges.View all ASND earnings summariesASND Stock 12 Month Forecast
Average Price Target
$293.77
▲(35.41% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Madrigal Pharmaceuticals
―
United Therapeutics
―
BridgeBio Pharma
―
Ownership Overview
Currently, No data available
---